Involved-field radiotherapy (IFRT) versus elective nodal irradiation (ENI) in combination with concurrent chemotherapy for 239 esophageal cancers: a single institutional retrospective study

被引:47
作者
Yamashita, Hideomi [1 ]
Takenaka, Ryousuke [1 ]
Omori, Mami [1 ]
Imae, Toshikazu [1 ]
Okuma, Kae [1 ]
Ohtomo, Kuni [1 ]
Nakagawa, Keiichi [1 ]
机构
[1] Tokyo Univ Hosp, Dept Radiol, Bunkyo Ku, Tokyo 1138655, Japan
来源
RADIATION ONCOLOGY | 2015年 / 10卷
关键词
SQUAMOUS-CELL CARCINOMA; DIAMMINE-GLYCOLATOPLATINUM NEDAPLATIN; CONFORMAL RADIATION-THERAPY; BLOOD PREDICTS RECURRENCE; DEFINITIVE CHEMORADIOTHERAPY; LUNG-CANCER; THORACIC ESOPHAGUS; SURGERY; CHEMORADIATION; 5-FLUOROURACIL;
D O I
10.1186/s13014-015-0482-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: This retrospective study on early and locally advanced esophageal cancer was conducted to evaluate locoregional failure and its impact on survival by comparing involved field radiotherapy (IFRT) with elective nodal irradiation (ENI) in combination with concurrent chemotherapy. Methods: We assessed all patients with esophageal cancer of stages I-IV treated with definitive radiotherapy from June 2000 to March 2014. Between 2000 and 2011, ENI was used for all cases excluding high age cases. After Feb 2011, a prospective study about IFRT was started, and therefore IFRT was used since then for all cases. Concurrent chemotherapy regimen was nedaplatin (80 mg/m(2) at D1 and D29) and 5-fluorouracil (800 mg/m(2) at D1-4 and D29-32). Results: Of the 239 consecutive patients assessed (120 ENI vs. 119 IFRT), 59 patients (24.7 %) had stage IV disease and all patients received at least one cycle of chemotherapy. The median follow-up time for survivors was 34.0 months. There were differences in 3-year local control (44.8 % vs. 55.5 %, p = 0.039), distant control (53.8 % vs. 69.9 %, p = 0.021) and overall survival (34.8 % vs. 51.6 %, p = 0.087) rates between ENI vs. IFRT, respectively. Patients treated with IFRT (8 %) demonstrated a significantly lower risk (p = 0.047) of high grade late toxicities than with ENI (16 %). IFRT did not increase the risk of initially uninvolved or isolated nodal failures (27.5 % in ENI and 13.4 % in IFRT). Conclusions: Nodal failure rates in clinically uninvolved nodal stations were not increased with IFRT when compared to ENI. IFRT also resulted in significantly decreased esophageal toxicity, suggesting that IFRT may allow for integration of concurrent systemic chemotherapy in a greater proportion of patients. Both tendencies of improved loco-regional progression-free survival and a significant increased overall survival rate favored the IFRT arm over the ENI arm in this study.
引用
收藏
页数:10
相关论文
共 9 条
  • [1] Comparison of involved field radiotherapy and elective nodal irradiation in combination with concurrent chemotherapy for T1bN0M0 esophageal cancer
    Nakatani, Yukihiro
    Kato, Ken
    Shoji, Hirokazu
    Iwasa, Satoru
    Honma, Yoshitaka
    Takashima, Atsuo
    Ushijima, Toshikazu
    Ito, Yoshinori
    Itami, Jun
    Boku, Narikazu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (06) : 1098 - 1104
  • [2] Feasibility of Elective Nodal Irradiation (ENI) and Involved Field Irradiation (IFI) in Radiotherapy for the Elderly Patients (Aged ≥ 70 Years) with Esophageal Squamous Cell Cancer: A Retrospective Analysis from a Single Institute
    Jing, Wang
    Zhu, Hui
    Guo, Hongbo
    Zhang, Yan
    Shi, Fang
    Han, Anqin
    Li, Minghuan
    Kong, Li
    Yu, Jinming
    PLOS ONE, 2015, 10 (12):
  • [3] Elective nodal irradiation or involved-field irradiation in definitive chemoradiotherapy for esophageal squamous cell cancer: a retrospective analysis in clinical N0 patients
    Sun, Y.
    Zhang, X. L.
    Mao, Q. F.
    Liu, Y. H.
    Kong, L.
    Li, M. H.
    CURRENT ONCOLOGY, 2018, 25 (05) : E423 - E429
  • [4] Elective nodal irradiation versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a network meta-analysis
    Liu, Tingting
    Ding, Silu
    Dang, Jun
    Wang, Hui
    Chen, Jun
    Li, Guang
    RADIATION ONCOLOGY, 2019, 14 (01)
  • [5] Elective nodal irradiation versus involved-field irradiation for stage II–IV cervical esophageal squamous cell carcinoma patients undergoing definitive concurrent chemoradiotherapy: a retrospective propensity study with 8-year survival outcomes
    Jianing Wang
    Yajing Wu
    Wei Zhang
    Yujia Chen
    Qing Liu
    Shaowu Jing
    Jiandong Zhang
    Fengpeng Wu
    Jun Wang
    Xueying Qiao
    Radiation Oncology, 18
  • [6] Elective nodal irradiation versus involved-field irradiation for stage II-IV cervical esophageal squamous cell carcinoma patients undergoing definitive concurrent chemoradiotherapy: a retrospective propensity study with 8-year survival outcomes
    Wang, Jianing
    Wu, Yajing
    Zhang, Wei
    Chen, Yujia
    Liu, Qing
    Jing, Shaowu
    Zhang, Jiandong
    Wu, Fengpeng
    Wang, Jun
    Qiao, Xueying
    RADIATION ONCOLOGY, 2023, 18 (01)
  • [7] Details of recurrence sites after elective nodal irradiation (ENI) using 3D-conformal radiotherapy (3D-CRT) combined with chemotherapy for thoracic esophageal squamous cell carcinoma - A retrospective analysis
    Yamashita, Hideomi
    Okuma, Kae
    Wakui, Reiko
    Kobayashi-Shibata, Shino
    Ohtomo, Kuni
    Nakagawa, Keiichi
    RADIOTHERAPY AND ONCOLOGY, 2011, 98 (02) : 255 - 260
  • [8] Involved-field irradiation or elective-nodal irradiation in neoadjuvant chemo-radiotherapy for locally-advanced esophageal cancer: comprehensive analysis for dosimetry, treatment-related complications, impact on lymphocyte, patterns of failure and survival
    Chen, Xianyan
    Zhang, Yingjie
    Zhou, Xiaojuan
    Wang, Min
    Na, Feifei
    Zhou, Lin
    Xu, Yong
    Zou, Bingwen
    Xue, Jianxin
    Liu, Yongmei
    Gong, Youling
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [9] The role of involved field irradiation versus elective nodal irradiation in definitive radiotherapy or chemoradiotherapy for esophageal cancer- a systematic review and meta-analysis
    Wang, Hesong
    Song, Chunyang
    Zhao, Xiaohan
    Deng, Wenzhao
    Shen, Wenbin
    FRONTIERS IN ONCOLOGY, 2022, 12